Kite Pharma

TECARTUS

View Prices
  1. Home
    2.  / 
  2. Q Code
    3.  / TECARTUS – Q2053

Manufacturer:

Kite Pharma

Name:

TECARTUS

HCPCS Code Descriptor:

Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Category:

Q Code

HCPCS:

Q2053

NDC(s):

71287-0220-01, 71287-0219-01

Primary Type:

Oncology

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

TECARTUS is an Oncology drug manufactured by Kite Pharma and administered via the Intravenous route of administration. The Q Code: Q2053 is aligned to the drug TECARTUS.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

4/1/21

HCPCS Effective Date:

4/1/21

HCPCS Short Description:

Brexucabtagene car pos t

Billing and Coding Guide:

Not Found

Patient Assistance:

https://www.kitekonnect.com/